These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 34741320)

  • 1. Molecular targets of psychedelic-induced plasticity.
    Jaster AM; de la Fuente Revenga M; González-Maeso J
    J Neurochem; 2022 Jul; 162(1):80-88. PubMed ID: 34741320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice.
    de la Fuente Revenga M; Zhu B; Guevara CA; Naler LB; Saunders JM; Zhou Z; Toneatti R; Sierra S; Wolstenholme JT; Beardsley PM; Huntley GW; Lu C; González-Maeso J
    Cell Rep; 2021 Oct; 37(3):109836. PubMed ID: 34686347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines.
    Cameron LP; Patel SD; Vargas MV; Barragan EV; Saeger HN; Warren HT; Chow WL; Gray JA; Olson DE
    ACS Chem Neurosci; 2023 Feb; 14(3):351-358. PubMed ID: 36630260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Models of psychedelic drug action: modulation of cortical-subcortical circuits.
    Doss MK; Madden MB; Gaddis A; Nebel MB; Griffiths RR; Mathur BN; Barrett FS
    Brain; 2022 Apr; 145(2):441-456. PubMed ID: 34897383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
    Majić T; Schmidt TT; Gallinat J
    J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemistry and Structure-Activity Relationships of Psychedelics.
    Nichols DE
    Curr Top Behav Neurosci; 2018; 36():1-43. PubMed ID: 28401524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychedelics: Where we are now, why we got here, what we must do.
    Belouin SJ; Henningfield JE
    Neuropharmacology; 2018 Nov; 142():7-19. PubMed ID: 29476779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.
    Canal CE
    Handb Exp Pharmacol; 2018; 252():227-260. PubMed ID: 29532180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychedelic Drugs in Biomedicine.
    Kyzar EJ; Nichols CD; Gainetdinov RR; Nichols DE; Kalueff AV
    Trends Pharmacol Sci; 2017 Nov; 38(11):992-1005. PubMed ID: 28947075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neurotrophic mechanisms of psychedelic therapy].
    Corne R; Mongeau R
    Biol Aujourdhui; 2019; 213(3-4):121-129. PubMed ID: 31829932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The renaissance in psychedelic research: What do preclinical models have to offer.
    Murnane KS
    Prog Brain Res; 2018; 242():25-67. PubMed ID: 30471682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Animal models of serotonergic psychedelics.
    Hanks JB; González-Maeso J
    ACS Chem Neurosci; 2013 Jan; 4(1):33-42. PubMed ID: 23336043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards an understanding of psychedelic-induced neuroplasticity.
    Calder AE; Hasler G
    Neuropsychopharmacology; 2023 Jan; 48(1):104-112. PubMed ID: 36123427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor.
    Preller KH; Burt JB; Ji JL; Schleifer CH; Adkinson BD; Stämpfli P; Seifritz E; Repovs G; Krystal JH; Murray JD; Vollenweider FX; Anticevic A
    Elife; 2018 Oct; 7():. PubMed ID: 30355445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hallucinogens and Serotonin 5-HT
    López-Giménez JF; González-Maeso J
    Curr Top Behav Neurosci; 2018; 36():45-73. PubMed ID: 28677096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deepening our understanding of psychedelics by expanding psychedelic data collection in the United States National Survey on Drug Use and Health.
    Barnett BS
    J Psychopharmacol; 2022 Oct; 36(10):1097-1099. PubMed ID: 36112818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible psychedelic therapeutic mechanism.
    Hess EM; Gould TD
    Science; 2023 Feb; 379(6633):642-643. PubMed ID: 36795807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure of a Hallucinogen-Activated Gq-Coupled 5-HT
    Kim K; Che T; Panova O; DiBerto JF; Lyu J; Krumm BE; Wacker D; Robertson MJ; Seven AB; Nichols DE; Shoichet BK; Skiniotis G; Roth BL
    Cell; 2020 Sep; 182(6):1574-1588.e19. PubMed ID: 32946782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.
    Erritzoe D; Smith J; Fisher PM; Carhart-Harris R; Frokjaer VG; Knudsen GM
    J Psychopharmacol; 2019 Sep; 33(9):1068-1075. PubMed ID: 30816797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.